Drug development will never be the same! AI is compressing time-to-market and extending the sales calendar for pharma. More profits from new medications. More new medications, too.

Many pharma and biotech stocks will boom as we enter the “sci-fi” stage of research and development. And this elite 8.8% dividend will directly benefit.

It typically takes 10 to 15 years to develop a new drug. Every month matters because patents last only 20 years. The faster a company gets a drug to market, the more months and years it enjoys with monopoly pricing power.

When patents expire, the generic versions hit the market.… Read more

Our favorite dividends are now on sale—but we still need to make sure we’re buying this dip the right way.

That means zeroing in on rich payers that not only throw off big divvies, but cushion our downside, too.

I’ve got two closed-end funds (CEFs) for you that do just that—and throw off rich 7%+ yields, too. And they avoid the deadly mistake most investors are making now.

Index Funds Pay Little, “Bargain” Techs Even Less

That mistake? Most investors are looking to beaten-down tech stocks (which pay zilch—or close to it!) or they’re grabbing a “plain vanilla” index fund, like the SPDR S&P 500 ETF Trust (SPY)—current yield: 1.1%

One-point-one-percent!… Read more

It never ceases to amaze me how many investors confuse investing with straight-up gambling.

Of course, we income investors know that gambling is a one-way ticket to losses (the house always wins, after all!). That’s why we always focus on long-term wealth creation (and a solid income stream) at my CEF Insider service, whose portfolio yields nearly 10% on average as I write this.

Nonetheless, with stocks having soared the way they have, it’s easier, even for normally prudent investors, to get caught up in dangerous speculation. That’s especially true when gambling seems to be everywhere these days.

Even though—a funny aside—gambling actually hasn’t grown as a percentage of Americans’ earnings in the last 25 years.… Read more

We contrarians follow Wall Street analysts because we like to fade their opinions!

When most say Buy, we are cautious. There is nobody left to upgrade these shares.

When they slap a Sell label, we are intrigued. So you’re saying the next rating change will be an upgrade?

These slippery suits rate most stocks Buys because, well, that’s the business. As we speak, 400 of the S&P 500 (!) is rated a Buy!

Even at All-Time Highs, Analysts Say 80% of the Market Is a Buy!

Source: S&P Global Market Intelligence

So let’s sift through the Holds and the Sells. Today we’ll sort through a four-pack yielding between 7.9% and 20.6%.… Read more

I’ve seen a lot more news stories trying to do something that seems a bit weird these days: stoke anger between generations.

I bring this up because it’s an example of why, when it comes to picking stocks (and 8%+ paying closed-end funds), we simply can’t trust the media anymore.

Why? Because many outlets are so focused on generating emotional responses (and the clicks that go with them) that they’ve gotten far away from what really matters: the real data behind what they’re saying.

With that in mind, we’re going to look at a data-driven indicator that tells us whether or not it’s a good time to buy.… Read more

Jerome Powell is preparing a wonderful holiday income dish for us.

The economy is running hot and he’s cutting rates anyway. Oh baby! “Lame Duck Jerry” is finally starting to cook.

But vanilla investors aren’t having it. They’re sprinting from the table! Recession fears dominate the headlines, even though the data scream otherwise.

The Atlanta Fed’s thermometer has GDP at a sizzling 4%. Four percent! In today’s AI-fueled, efficiency-obsessed economy, the old recession playbook simply doesn’t apply.

AI is eating traditional white-collar work. Business models from 2019 no longer apply in 2025. Some sectors are struggling while others hit new strides.… Read more

What a time to be a contrarian!

The economy is en fuego as AI boosts productivity (even if, yes, it’s cooling payrolls). Yet the mainstream crowd is hunkered down, terrified of an AI bubble.

That sets up some very attractive deals in 8%-paying closed-end funds (CEFs), many of which have gone on sale in the last few weeks.

2 “North Stars” Show Us What to Do Now

To get a feel for the setup in front of us, all we need to do is look at two things.

First, the Atlanta Fed’s GDPNow indicator, the most current economic “barometer” we have.… Read more

It’s been a long time since we talked about pandemic bargains, but believe it or not, there’s still a big one out there.

I do think it’s finally on borrowed time, though, which is why it’s on our radar now.

I’m talking about publicly traded real estate investment trusts (REITs). What we’re looking at with REITs is a classic “buy the dip” play with a (very!) long buy window indeed. Here’s a snapshot:

REITs Trail Stocks Post-Pandemic …

Over the five years since the depths of the pandemic, the S&P 500 (shown by the popular index fund in purple above) has posted a 106.5% total return, as of this writing.… Read more

Will the stock market finish the year higher or lower?

Who cares?!

Paying attention to “the market” is a hopeless effort in 2025. The explosion of AI implementation plus the policies from Trump 2.0 are creating winners and losers in the economy.

So why buy a basket when we can cherry pick the undervalued front runners?

Even better? Some are cheap! As I write, four big dividend payers (dishing divvies between 5% and 6%) are trading at bargain-basement valuations. Let’s start with the most established of the four-pack, trading for less than its annual sales…

Sonoco Products (SON)
Dividend Yield: 5.2%

Sonoco Products (SON) is a packaging dinosaur turned value play.… Read more

Selling on fear is a habit that’s so easy to fall into (especially now!). But giving in to it could cost you a lot: as much as $2,300 on every $10K invested.

And if you’re investing for income (as we are!), you face a double hit.

Not only do investors almost always get the timing wrong, but they cut off their income stream, too! When you’re holding our favorite income plays, closed-end funds (CEFs) yielding 8%+, it’s especially damaging.

I mention this now because I was reading a recent report from Morningstar that put the potential damage from this mistake into dollars and cents.… Read more